These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12473539)

  • 1. Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: a cup half full.
    Kereiakes DJ
    Circulation; 2002 Dec; 106(24):2994-6. PubMed ID: 12473539
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ
    Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of glycoprotein IIb/IIIa inhibitors in the treatment of degenerated aortocoronary saphenous vein grafts].
    Brück M; Ludwig J; Flachskampf FA; Daniel WG
    Z Kardiol; 2002 Jan; 91(1):16-23. PubMed ID: 11963202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited.
    Tang WH; Lincoff AM
    Circulation; 2004 Dec; 110(24):3618-20. PubMed ID: 15596556
    [No Abstract]   [Full Text] [Related]  

  • 6. [Investigation into the cause of re-stenosis after coronary bypass surgery].
    Fujimoto Y
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():595-9. PubMed ID: 12735037
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
    Roffi M; Mukherjee D; Chew DP; Bhatt DL; Cho L; Robbins MA; Ziada KM; Brennan DM; Ellis SG; Topol EJ
    Circulation; 2002 Dec; 106(24):3063-7. PubMed ID: 12473552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade.
    Lincoff AM
    Circulation; 2003 Mar; 107(11):1556-9. PubMed ID: 12654616
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
    Kalyanasundaram A; Blankenship JC; Berger P; Herrmann H; McClure R; Moliterno D
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):623-9. PubMed ID: 17192960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late outcomes after intervention of vein grafts in diabetics with abciximab use.
    Applegate RJ; Upadhya B; Little WC; Xenakis M; Gandhi SK; Baki TT; Kahl FR; Kutcher MA
    Int J Cardiol; 2006 Jul; 111(1):136-41. PubMed ID: 16226815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM
    Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Should treatment with glycoprotein IIa/IIIb receptor blocker be controlled in patients undergoing coronary intervention?].
    Heras M
    Rev Esp Cardiol; 2001 Nov; 54(11):1251-3. PubMed ID: 11707232
    [No Abstract]   [Full Text] [Related]  

  • 19. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
    Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
    Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Gambassi G; Landolfi R; Bernabei R
    N Engl J Med; 1997 Oct; 337(17):1243-4. PubMed ID: 9340528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.